Elutia Inc.
corporate_fare Company Profile
Elutia Inc. (NASDAQ:ELUT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for ELUT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for ELUT spans 8-K, 10-Q, DEF 14A, 10-K.
Recent high-impact activity:
- Elutia Posts $1.1M Q3 Sales, Confirms NXT-41x FDA Filing This Quarter With $29.1M Cash
- Elutia Q3: $1.1M Sales, $29.1M Cash, NXT-41x FDA Filing Set for Q4
- Elutia Closes SimpliDerm Sale, Receives $7.7M Cash to Fund NXT-41x Launch
- Elutia Faces Nasdaq Delisting, Secures $15M Loan, and Divests SimpliDerm
- Elutia Posts Q2 Loss but Says Funding Is in Place Through NXT-41x Launch Without Equity Offering
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 33,661 shares in ELUT as of the October 30, 2026 settlement, a 119.6% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 15.0% of ELUT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.